An overview of challenges that remain in the treatment of patients with AL amyloidosis

Rahel Schwotzer, MD, University Hospital Zürich, Zürich, Switzerland, discusses the remaining challenges for patients with light chain (AL) amyloidosis, emphasizing the lack of therapeutic options available to those who relapse or do not respond to initial treatment. For those with the t(11;14) translocation, venetoclax is a promising agent, however, an unmet need remains in non-t(11;14) patients. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.